PUBLISHED DATE : May 2022 | Pages : 190
Fill out your details & get your free sample
The Graft Versus Host Disease (GVHD) Treatment Market Size, Share, & Trends Analysis Report by
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2022–2027.
190 Pages
6 Tables
134 Charts
3 Regions
8 Countries
25 Companies
5 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size (2027) | USD 990 Million |
| Market Size (2021) | USD 643 MILLION |
| CAGR (2022-2027) | 7.44% |
| Base Year | 2021 |
| Forecast Year | 2022-2027 |
| Countries Covered | US, France, Germany, Italy, UK, China, Japan and Spain |
| Geographic Analysis | North America, Europe, APAC |
Graft Versus Host Disease treatment market was valued at USD 643 million in 2021 and is expected to reach USD 990 million by 2027, growing at a CAGR of 7.44%.
GVHD is a condition that occurs when immune cells (T-cells) after transplant procedures from the donor (known as the graft or graft cells) attack the recipient patient host’s tissues (healthy cells).
According to the estimates, the highest number of HSCTs is accessed in the United States, followed by China and Germany in 2020. The demand for Allo-HSCT is increasing faster. The trend is likely to continue during the forecast period due to the rising incidence of leukemia and lymphoma, rise in success rates of transplantation, and increase in the aging population.
Market Dynamics:
Opportunities:
Corticosteroids drugs are expected to account for a significant share of the global graft versus host disease treatment market. However, the kinase inhibitors are expected to be the fastest-growing segment during the forecast period. Physicians recommend corticosteroids as a front-line therapy due to their proven safety and efficacy. In addition, the alternative drugs have less proven safety and efficacy, driving the physicians to recommend the corticosteroids only in front-line therapy.
The acute GVHD (aGVHD) is expected to account for a significant share of the global market. For instance, a research study published by the National Center of Biotechnology Information in 2020 suggests that around 30% to 50% of hematopoietic stem cell transplant recipients develop acute GVHD.
Gender type: Among the gender type, males are expected to dominate the market. However, females are expected to be the fastest-growing segment during the forecast period. In males, a rise in hematopoietic stem cell transplantations is projected to augment the segment during the forecast period.
The United States dominated the graft versus host disease treatment market by geography. However, China is expected to grow faster with a high CAGR. The rise in incidence and prevalence of GVHD patients, presence of key players, and rise in access to health care due to well-established healthcare infrastructure and extensive reach of novel therapeutics are largely driving the United States market.
The GVHD treatment market is dominated by many companies offering generic and off-label drugs and selective pharma/biotech companies offering patented/commercial drugs for treating GVHD. The companies offering patented drugs for GVHD include Kadmon, Incyte Corp, Pharmacyclics, Bristol Myers Squibb, and Mesoblast. With more than 135 molecules in various stages of development, it is expected that new vendors are likely to enter the market with a novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating GVHD.
The Report Covers The following details:
Frequently Asked Questions
WHAT WILL BE THE SIZE OF THE GVHD MARKET BY 2027?
The graft versus host disease market is expected to reach USD 990.16 million by 2027, growing at a CAGR of 7.44% during 2021-2027
WHAT ARE THE OPPORTUNITIES FOR VENDORS IN THE GRAFT VERSUS HOST DISEASE MARKET?
High investments in R&D capabilities and infrastructure by the industry and governments are anticipated to create lucrative opportunities in the market.
WHO ARE THE KEY PLAYERS IN THE GRAFT VERSUS HOST DISEASE TREATMENT MARKET?
Key vendors include Incyte, Pharmacyclics, Bristol-Myers Squibb, JCR Pharmaceuticals Co., Ltd., Takeda Pharmaceutical Co Ltd (Takeda), and MaaT Pharma.
WHAT ARE THE FUTURE PROJECTION FOR THE TREATMENT OF THE GVHD MARKET?
In the next years, new monoclonal antibodies and inhibitors of critical costimulatory molecules will increase the therapeutic strategies for the prevention or treatment of patients with acute GVHD.
The graft versus host disease market to grow at a CAGR of 7.44% during 2021-2027.
The following factors are likely to contribute to the growth of the market during the forecast period:
Base Year: 2021
Forecast Year: 2022-2027
The report considers the present scenario of the graft versus host disease market and its market dynamics for the period 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyses leading companies and several other prominent companies operating in the market.
Key Players
Other Prominent Vendors
Market Segmentation by Drug Class
Market Segmentation by Treatment Type
Market Segmentation by Gender Type
Market Segmentation by Geography
CHAPTER – 1: GVHD OVERVIEW
CHAPTER – 2: GVHD EPIDEMIOLOGY & OVERVIEW
CHAPTER – 3: GVHD MARKET SIZE & OVERVIEW
CHAPTER – 4: GVHD MARKETED DRUGS OVERVIEW
CHAPTER – 5: GVHD PIPELINE DRUGS OVERVIEW
CHAPTER – 6: GVHD CLINICAL TRIALS OVERVIEW
CHAPTER – 7: GVHD MARKET DYNAMICS
CHAPTER – 8: GVHD COMPETITIVE LANDSCAPE
CHAPTER – 9: GVHD MISCELLANEOUS
CHAPTER – 10: APPENDIX
LIST OF EXHIBITS
Exhibit 1 HISTORIC & PROJECTED VOLUME OF HSCT IN 8 MAJOR MARKETS
Exhibit 2 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN 8 MAJOR MARKETS
Exhibit 3 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN 8 MAJOR MARKETS (2018-2020)
Exhibit 4 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 5 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN 8 MAJOR MARKETS
Exhibit 6 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN 8 MAJOR MARKETS
Exhibit 7 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN 8 MAJOR MARKETS (2018-2020)
Exhibit 8 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN 8 MAJOR MARKETS (2021-2027)
Exhibit 9 HISTORIC & PROJECTED VOLUME OF HSCT IN UNITED STATES
Exhibit 10 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN UNITED STATES
Exhibit 11 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED STATES (2018-2020)
Exhibit 12 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED STATES (2021-2027)
Exhibit 13 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN UNITED STATES
Exhibit 14 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN UNITED STATES
Exhibit 15 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED STATES (2018-2020)
Exhibit 16 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED STATES (2021-2027)
Exhibit 17 HISTORIC & PROJECTED VOLUME OF HSCT IN CHINA
Exhibit 18 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN CHINA
Exhibit 19 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN CHINA (2018-2020)
Exhibit 20 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN CHINA (2021-2027)
Exhibit 21 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN CHINA
Exhibit 22 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN CHINA
Exhibit 23 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN CHINA (2018-2020)
Exhibit 24 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN CHINA (2021-2027)
Exhibit 25 HISTORIC & PROJECTED VOLUME OF HSCT IN GERMANY
Exhibit 26 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN GERMANY
Exhibit 27 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN GERMANY (2018-2020)
Exhibit 28 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN GERMANY (2021-2027)
Exhibit 29 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN GERMANY
Exhibit 30 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN GERMANY
Exhibit 31 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN GERMANY (2018-2020)
Exhibit 32 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN GERMANY (2021-2027)
Exhibit 33 HISTORIC & PROJECTED VOLUME OF HSCT IN JAPAN
Exhibit 34 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN JAPAN
Exhibit 35 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN JAPAN (2018-2020)
Exhibit 36 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN JAPAN (2021-2027)
Exhibit 37 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN JAPAN
Exhibit 38 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN JAPAN
Exhibit 39 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN JAPAN (2018-2020)
Exhibit 40 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN JAPAN (2021-2027)
Exhibit 41 HISTORIC & PROJECTED VOLUME OF HSCT IN FRANCE
Exhibit 42 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN FRANCE
Exhibit 43 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN FRANCE (2018-2020)
Exhibit 44 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN FRANCE (2021-2027)
Exhibit 45 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN FRANCE
Exhibit 46 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN FRANCE
Exhibit 47 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN FRANCE (2018-2020)
Exhibit 48 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN FRANCE (2021-2027)
Exhibit 49 HISTORIC & PROJECTED VOLUME OF HSCT IN ITALY
Exhibit 50 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN ITALY
Exhibit 51 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN ITALY (2018-2020)
Exhibit 52 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN ITALY (2021-2027)
Exhibit 53 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN ITALY
Exhibit 54 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN ITALY
Exhibit 55 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN ITALY (2018-2020)
Exhibit 56 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN ITALY (2021-2027)
Exhibit 57 HISTORIC & PROJECTED VOLUME OF HSCT IN UNITED KINGDOM
Exhibit 58 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN UNITED KINGDOM
Exhibit 59 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED KINGDOM (2018-2020)
Exhibit 60 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED KINGDOM (2021-2027)
Exhibit 61 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN UNITED KINGDOM
Exhibit 62 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN UNITED KINGDOM
Exhibit 63 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED KINGDOM (2018-2020)
Exhibit 64 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED KINGDOM (2021-2027)
Exhibit 65 HISTORIC & PROJECTED VOLUME OF HSCT IN SPAIN
Exhibit 66 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN SPAIN
Exhibit 67 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN SPAIN (2018-2020)
Exhibit 68 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN SPAIN (2021-2027)
Exhibit 69 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN SPAIN
Exhibit 70 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN SPAIN
Exhibit 71 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN SPAIN (2018-2020)
Exhibit 72 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN SPAIN (2021-2027)
Exhibit 73 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN 8 MAJOR MARKETS
Exhibit 74 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN 8 MAJOR MARKETS
Exhibit 75 MAJOR APPROVED & OFF-LABEL DRUGS IN GVHD TREATMENT MARKET
Exhibit 76 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN 8 MAJOR MARKETS
Exhibit 77 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN 8 MAJOR MARKETS
Exhibit 78 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN 8 MAJOR MARKETS
Exhibit 79 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN UNITED STATES
Exhibit 80 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN UNITED STATES
Exhibit 81 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN UNITED STATES
Exhibit 82 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN UNITED STATES
Exhibit 83 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN UNITED STATES
Exhibit 84 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN CHINA
Exhibit 85 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN CHINA
Exhibit 86 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN CHINA
Exhibit 87 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN CHINA
Exhibit 88 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN CHINA
Exhibit 89 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN GERMANY
Exhibit 90 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN GERMANY
Exhibit 91 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN GERMANY
Exhibit 92 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN GERMANY
Exhibit 93 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN GERMANY
Exhibit 94 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN JAPAN
Exhibit 95 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN JAPAN
Exhibit 96 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN JAPAN
Exhibit 97 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN JAPAN
Exhibit 98 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN JAPAN
Exhibit 99 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN FRANCE
Exhibit 100 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN FRANCE
Exhibit 101 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN FRANCE
Exhibit 102 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN FRANCE
Exhibit 103 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN FRANCE
Exhibit 104 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN ITALY
Exhibit 105 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN ITALY
Exhibit 106 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN ITALY
Exhibit 107 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN ITALY
Exhibit 108 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN ITALY
Exhibit 109 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN UNITED KINGDOM
Exhibit 110 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN UNITED KINGDOM
Exhibit 111 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN UNITED KINGDOM
Exhibit 112 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN UNITED KINGDOM
Exhibit 113 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN UNITED KINGDOM
Exhibit 114 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN SPAIN
Exhibit 115 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN SPAIN
Exhibit 116 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN SPAIN
Exhibit 117 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN SPAIN
Exhibit 118 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN SPAIN
Exhibit 119 MARKETED DRUGS OVERVIEW IN GVHD TREATMENT MARKET
Exhibit 120 GVHD PIPELINE DRUGS OVERVIEW SNAPSHOT
Exhibit 121 GVHD PIPELINE DRUGS LANDSCAPE SNAPSHOT
Exhibit 122 GVHD PIPELINE DRUGS OVERVIEW BY DISEASE TYPE
Exhibit 123 GVHD PIPELINE DRUGS OVERVIEW BY DEVELOPMENT PHASE
Exhibit 124 GVHD PIPELINE DRUGS OVERVIEW BY ROUTE OF ADMINISTRATION
Exhibit 125 GVHD PIPELINE DRUGS OVERVIEW BY MECHANISM OF ACTION
Exhibit 126 GVHD PIPELINE DRUGS OVERVIEW BY MOLECULE TYPE
Exhibit 127 GVHD PIPELINE DRUGS OVERVIEW BY GEOGRAPHY TYPE
Exhibit 128 KEY TENTATIVE TIMELINE APPROVALS OF PIPELINE DRUHS IN GVHD
Exhibit 129 KEY REGULATORY DESIGNATIONS OF PIPELINE DRUGS IN GVHD
Exhibit 130 INACTIVE/DISCONTINUED PIPELINE DRUGS IN GVHD
Exhibit 131 COMPETITIVE ASSESSMENT OF GVHD PROPHYLAXIS OFF-LABEL & LATE-STAGE PIPELINE DRUGS
Exhibit 132 COMPETITIVE ASSESSMENT OF ACUTE GVHD OFF-LABEL & LATE-STAGE PIPELINE DRUGS
Exhibit 133 COMPETITIVE ASSESSMENT OF CHRONIC GVHD OFF-LABEL & LATE-STAGE PIPELINE DRUGS
Exhibit 134 GVHD CLINICAL TRIALS OVERVIEW SNAPSHOT
LIST OF TABLES
Table 1 KEY MARKET DRIVERS IN GVHD TREATMENT MARKET
Table 2 KEY MARKET CONSTRAINTS IN GVHD TREATMENT MARKET
Table 3 KEY MARKET TRENDS IN GVHD TREATMENT MARKET
Table 4 COMPETITIVE LANDSCAPE OF MARKETED DRUGS IN GVHD TREATMENT MARKET
Table 5 COMPETITIVE SCENARIO OF GVHD TREATMENT MARKET
Table 6 COMPETITIVE LANDSCAPE OF PIPELINE DRUGS IN GVHD TREATMENT MARKET
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
